ArticleBMC cancer2025
Impact of uterine adenomyosis on survival outcome of patients with non-endometrioid endometrial cancer.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Adenomyosis is not an independent prognostic factor in endometrioid-type endometrial cancer.Irish journal of medical science · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe impact of the presence of adenomyosis on survival in patients with non-endometrioid endometrial cancer (EC) remains unclear. The aim of this study is to compare the effect of the presence or absence of histologically proven adenomyosis on the survival of patients with non-endometrioid EC.
methodsWe identified all patients who were consecutively diagnosed with non-endometrioid EC and underwent surgery in a single center between May 1998 and March 2023. Patients with insufficient clinical or surgical data were excluded from the study. A total of 139 non-endometrioid EC patients in the study were divided into two groups as with and without adenomyosis. Demographic characteristics and clinical findings such as age, BMI, menopausal status and pathologic variables such as presence of adenomyosis, tumor grade, depth of myometrial invasion, lymphovascular space involvement, lymph node status, and distant spread were obtained hospital records. Kaplan Meier analysis was performed for survival analysis. Overall (OS), and disease-free survival (DFS) were calculated.
resultsA total of 139 patients, 40 (28.7%) in the adenomyosis group and 99 (71.3%) in the non-adenomyosis group, were included in the study and their data were recorded.There was no significant difference between patients with non-endometrioid type EC with and without adenomyosis in terms of patient demographic characteristics and pathological variables (p > 0.05).When the patients in the adenomyosis and non-adenomyosis groups were compared, there was no statistically significance regarding recurrence time (175.2 ± 24.4 months vs. 95.1 ± 11.2 months, p = 0.166). However, OS was found to be statistically significantly higher in patients with adenomyosis than in those without adenomyosis (172 ± 24.1 months vs. 102 ± 13.9 months; p = 0.02).
conclusionsThe presence of adenomyosis in non-endometrioid type endometrial cancer was not associated with pathological variables such as myometrial invasion, tumor diameter and lympho-vascular space involvement. Although DFS and cancer-related death rates were similar, OS was significantly higher in the presence of adenomyosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.